203 related articles for article (PubMed ID: 22615105)
1. In situ crosslinkable heparin-containing poly(ethylene glycol) hydrogels for sustained anticoagulant release.
Baldwin AD; Robinson KG; Militar JL; Derby CD; Kiick KL; Akins RE
J Biomed Mater Res A; 2012 Aug; 100(8):2106-18. PubMed ID: 22615105
[TBL] [Abstract][Full Text] [Related]
2. Rheological characterization of polysaccharide-poly(ethylene glycol) star copolymer hydrogels.
Yamaguchi N; Chae BS; Zhang L; Kiick KL; Furst EM
Biomacromolecules; 2005; 6(4):1931-40. PubMed ID: 16004430
[TBL] [Abstract][Full Text] [Related]
3. Prolonged subcutaneous delivery of low molecular weight heparin based on thermoresponsive hydrogels with chitosan nanocomplexes: Design, in vitro evaluation, and cytotoxicity studies.
Radivojša Matanović M; Grabnar I; Gosenca M; Grabnar PA
Int J Pharm; 2015 Jul; 488(1-2):127-35. PubMed ID: 25912230
[TBL] [Abstract][Full Text] [Related]
4. In situ chemically crosslinked injectable hydrogels for the subcutaneous delivery of trastuzumab to treat breast cancer.
Lo YW; Sheu MT; Chiang WH; Chiu YL; Tu CM; Wang WY; Wu MH; Wang YC; Lu M; Ho HO
Acta Biomater; 2019 Mar; 86():280-290. PubMed ID: 30616077
[TBL] [Abstract][Full Text] [Related]
5. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor.
Cai S; Liu Y; Zheng Shu X; Prestwich GD
Biomaterials; 2005 Oct; 26(30):6054-67. PubMed ID: 15958243
[TBL] [Abstract][Full Text] [Related]
6. Production of heparin-containing hydrogels for modulating cell responses.
Nie T; Akins RE; Kiick KL
Acta Biomater; 2009 Mar; 5(3):865-75. PubMed ID: 19167277
[TBL] [Abstract][Full Text] [Related]
7. Polysaccharide-poly(ethylene glycol) star copolymer as a scaffold for the production of bioactive hydrogels.
Yamaguchi N; Kiick KL
Biomacromolecules; 2005; 6(4):1921-30. PubMed ID: 16004429
[TBL] [Abstract][Full Text] [Related]
8. Ultrafast in situ forming poly(ethylene glycol)-poly(amido amine) hydrogels with tunable drug release properties via controllable degradation rates.
Buwalda SJ; Bethry A; Hunger S; Kandoussi S; Coudane J; Nottelet B
Eur J Pharm Biopharm; 2019 Jun; 139():232-239. PubMed ID: 30954658
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
[TBL] [Abstract][Full Text] [Related]
10. Design and evaluation of novel fast forming pilocarpine-loaded ocular hydrogels for sustained pharmacological response.
Anumolu SS; Singh Y; Gao D; Stein S; Sinko PJ
J Control Release; 2009 Jul; 137(2):152-9. PubMed ID: 19341773
[TBL] [Abstract][Full Text] [Related]
11. Development of PEG-PLGA based Intravenous Low Molecular Weight Heparin (LMWH) Nanoparticles Intended to Treat Venous Thrombosis.
Jogala S; Rachamalla SS; Aukunuru J
Curr Drug Deliv; 2016; 13(5):698-710. PubMed ID: 26777886
[TBL] [Abstract][Full Text] [Related]
12. Novel injectable biodegradable glycol chitosan-based hydrogels crosslinked by Michael-type addition reaction with oligo(acryloyl carbonate)-b-poly(ethylene glycol)-b-oligo(acryloyl carbonate) copolymers.
Yu Y; Deng C; Meng F; Shi Q; Feijen J; Zhong Z
J Biomed Mater Res A; 2011 Nov; 99(2):316-26. PubMed ID: 21887740
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of heparin and LMWH using a fibrin antibody prevents restenosis.
Thomas AC; Campbell JH
Atherosclerosis; 2004 Sep; 176(1):73-81. PubMed ID: 15306177
[TBL] [Abstract][Full Text] [Related]
14. Diels-Alder hydrogels with enhanced stability: First step toward controlled release of bevacizumab.
Kirchhof S; Gregoritza M; Messmann V; Hammer N; Goepferich AM; Brandl FP
Eur J Pharm Biopharm; 2015 Oct; 96():217-25. PubMed ID: 26253504
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo protein delivery from in situ forming poly(ethylene glycol)-poly(lactide) hydrogels.
Hiemstra C; Zhong Z; Van Tomme SR; van Steenbergen MJ; Jacobs JJ; Otter WD; Hennink WE; Feijen J
J Control Release; 2007 Jun; 119(3):320-7. PubMed ID: 17475360
[TBL] [Abstract][Full Text] [Related]
16. Novel degradable poly(ethylene glycol) hydrogels for controlled release of protein.
Zhao X; Harris JM
J Pharm Sci; 1998 Nov; 87(11):1450-8. PubMed ID: 9811505
[TBL] [Abstract][Full Text] [Related]
17. Sustained release of low molecular weight heparin from PLGA microspheres prepared by a solid-in-oil-in-water emulsion method.
He J; Zhou Z; Fan Y; Zhou X; Du H
J Microencapsul; 2011; 28(8):763-70. PubMed ID: 22034953
[TBL] [Abstract][Full Text] [Related]
18. PEG-cross-linked heparin is an affinity hydrogel for sustained release of vascular endothelial growth factor.
Tae G; Scatena M; Stayton PS; Hoffman AS
J Biomater Sci Polym Ed; 2006; 17(1-2):187-97. PubMed ID: 16411608
[TBL] [Abstract][Full Text] [Related]
19. In vivo bone and soft tissue response to injectable, biodegradable oligo(poly(ethylene glycol) fumarate) hydrogels.
Shin H; Quinten Ruhé P; Mikos AG; Jansen JA
Biomaterials; 2003 Aug; 24(19):3201-11. PubMed ID: 12763447
[TBL] [Abstract][Full Text] [Related]
20. Single and dual crosslinked oxidized methacrylated alginate/PEG hydrogels for bioadhesive applications.
Jeon O; Samorezov JE; Alsberg E
Acta Biomater; 2014 Jan; 10(1):47-55. PubMed ID: 24035886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
